When to Use NIR-II Imaging — and When Not To

NIR-II Imaging

Preclinical

Updated:

May 22, 2026

When to Use NIR-II Imaging — and When Not To

NIR-II imaging is not simply a longer-wavelength alternative to NIR-I. It enables specific biological questions to be addressed that are difficult—or impossible—to resolve with shorter wavelengths. At the same time, some applications remain better served by bioluminescence. A strategic modality decision begins with the biological endpoint.

SUMMARY

The decision in 30 seconds‍

‍

NIR-II imaging (1000–1700 nm) offers superior penetration depth and reduced photon scattering compared to traditional NIR-I and visible wavelengths, making it ideal for deep-tissue visualization, real-time drug distribution studies, and cardiovascular mapping in preclinical research.

‍

The most informative studies increasingly combine both modalities : bioluminescence for molecular sensitivity + NIR-II for deep anatomical context, enabling researchers to correlate biological activity with structural and pharmacological distribution in the same imaging session.

‍

Choose NIR-II for: depth, scattering reduction, vascular resolution, drug distribution clarity
Choose bioluminescence for: molecular sensitivity, low cell detection, gene expression reporting

When to use NIR-II

‍

1 — Deep-tissue imaging where scattering limits NIR-I

‍

NIR-II (1000–1700 nm) significantly reduces photon scattering and tissue autofluorescencecompared to NIR-I. This translates into improved penetration depth and signal-to-noise ratiosfor biological targets located several millimeters below the surface.

‍

Use NIR-II when:

Monitoring liver, pancreas, or brain targets
Imaging deep orthotopic tumors
Studying biodistribution in metabolically active organs
Working in larger animal models

‍

For these applications, improved penetration depth directly improves interpretability and quantification.

‍

Criterion	NIR-I (700–900 nm)	NIR-II (1000–1700 nm)	Bioluminescence
Penetration depth	~1–2 mm	~5–10 mm Best	Variable, depth-limited
Tissue scattering	Moderate	Low	N/A
Autofluorescence	Moderate	Very low	None Best
Molecular sensitivity	Moderate	Moderate	Very high Best
Real-time imaging	✓	✓	Limited
Best use case	Surface fluorescence	Deep-tissue, vascular, drug distribution	Cellular viability, gene expression

‍

2 — Real-time drug distribution and metabolic imaging

‍

NIR-II is particularly well suited for tracking pharmacokinetics, monitoring probe clearancepathways, and imaging metabolic organ perfusion in real time. The combination of lowbackground and improved deep-organ contrast enables clearer visualization of drugaccumulation and washout kinetics.

‍

NIR-II is particularly well suited for:

Real-time pharmacokinetics
Dynamic biodistribution studies
Monitoring probe clearance pathways
Imaging metabolic organ perfusion
Reduced background and higher deep-organ contrast enable clearer visualization of drug accumulation and washout kinetics.

‍

For translational research andpreclinical drug development, this can provide a more accurate understanding oftissue targeting and systemic exposure.

‍

2 — Cardiovascular mapping

‍

The reduced scattering in NIR-II allows improved visualization of:

Vascular architecture
Microvascular perfusion
Cardiac and cerebral blood flow patterns
Real-time vascular dynamics

‍

For high-speed imaging of vascular filling or contrast agent propagation, NIR-II provides improved vessel delineation in deep tissue compared to NIR-I.

‍

4 — Probe development and validation

‍

NIR-II is increasingly used in the development of:

Organic long-wavelength fluorophores
Rare-earth nanoparticles
Small-molecule NIR-II dyes
Targeted conjugates

‍

NIR-II platforms allow proper evaluation of probe brightness, targeting specificity, and clearance.

‍

When bioluminescence is the better choice

‍

While NIR-II excels in deep-tissue structural and distribution imaging, bioluminescence remains unmatched in sensitivity for certain molecular processes.

‍

1 — Detection of molecular and cellular activity

‍

Bioluminescence offers:

Extremely low background
High sensitivity for small cell populations
Direct reporting of gene expression
Monitoring of promoter activity
Early tumor cell detection

‍

For studies focused on cellular viability, molecular signaling, or reporter gene expression, bioluminescence often provides superior sensitivity compared to fluorescence modalities.

‍

When to combine modalities

‍

Increasingly, the most informativestudies use both Bioluminescence and NIR-II modalities together.

‍

Bioluminescence → unrivalled sensitivity for molecular processes
NIR-II → deep-tissue anatomical and biodistribution visualization
Optional NIR-I → targeted superficial imaging

Example workflow:

Luciferase reports tumor viability
NIR-II probe maps drug accumulation in deep tumor mass
Anatomical overlay improves spatial interpretation

‍

This combination allows researchers to correlate biological activity with structural and pharmacological distribution in the same animal, in the same imaging session.

‍

When NIR-II may not be necessary

‍

Superficial subcutaneous models
Early screening studies focused solely on viability
High-throughput assays where deep visualization is not required
Experiments using well-validated NIR-I probes with sufficient depth

‍

In these cases, system complexity may not add scientific value.

‍

Decision framework

‍

Choose NIR-II when the limiting factor is:

Depth
Scattering
Autofluorescence
Vascular resolution
Drug distribution clarity

‍

Choose bioluminescence when the limiting factor is:

Sensitivity
Detection of low cell numbers
Gene expression reporting

‍

Combine modalities when the study requires both molecular sensitivity and deep anatomical context.

‍

Frequently asked questions

To quantify a Western blot, acquire the image within the linear dynamic range of your imaging system, ensure no bands are saturated, define a region of interest (ROI) around each band of interest plus a background ROI, calculate integrated optical density (IOD) for each, subtract background, and normalize to a loading control (preferably total protein). Express results as fold change relative to a control sample, and validate the linear range with a calibration curve at the start of the project.

For quantitative comparisons across abundance classes (low-abundance signaling proteins vs abundant housekeeping markers in the same lysate), you need at least 3 orders of magnitude (10³) of dynamic range. Modern systems deliver 4 to 5 orders, which eliminates the need for multiple exposures and stitched images.

Both can produce quantitative results when used correctly. Chemiluminescence offers higher peak sensitivity for very low-abundance proteins. Fluorescence offers wider dynamic range, multiplexing capability, and signal stability over time. For most modern protein analysis and quantitative workflows, fluorescence is preferred unless target abundance is below the chemiluminescence detection limit.

Housekeeping proteins (GAPDH, β-actin, α-tubulin) were assumed to be invariant across conditions, but multiple studies have shown they vary with treatment, time, cell type, and stress. Total protein normalization (Stain-Free, fluorescent stains) is now the methodological default for quantitative work, and is increasingly required by reviewers.

Dynamic range is the ratio between the strongest signal a sensor can record without saturation and the weakest signal it can detect above background. Expressed in orders of magnitude (or stops), it determines whether weak and strong bands on the same blot can be quantified in a single acquisition. Higher dynamic range means fewer exposures and more reliable comparisons.

Yes, when used by an experienced operator with consistent ROI placement, background subtraction, and analysis protocol. ImageJ does not enforce any quality control, so operator discipline replaces software guardrails. For routine quantification, native imaging system software or dedicated quantification platforms reduce operator variability.

NIST-traceable calibration provides absolute signal references that are reproducible across instruments, days, and sites. Without it, quantitative comparisons are limited to the same instrument on the same day. With it, longitudinal studies and multi-site collaborations become statistically valid. It is increasingly expected for regulatory work and high-impact publications.

The linear range is the interval over which signal intensity is proportional to protein quantity. Below the linear range, signal is dominated by noise. Above the linear range, the sensor saturates and signal does not increase with additional protein. Quantification is reliable only within the linear range, which is established empirically with a calibration curve.

Single exposures from a system with adequate dynamic range are preferable. Multiple exposures introduce stitching artifacts and inter-exposure variability that compromise quantification. If your system requires multiple exposures to span the abundance range of your samples, the system has insufficient dynamic range for the application.

Define the experimental program first: target abundance range, multiplexing needs, throughput requirements, normalization workflow, and quantification standards. Then evaluate systems against eight criteria: dynamic range, sensor sensitivity, detection chemistries supported, multiplexing channels, automation features, calibration traceability, software depth, and modular upgradability. Teams in evaluation phase can request a demo to test specific configurations against representative samples before committing.

‍

Key takeaways

What to remember

NIR-II (1000–1700 nm) is the modality of choice for deep-tissue imaging, vascular mapping, and real-time drug distribution.
Bioluminescence remains unmatched for molecular sensitivity, low-cell detection, and gene expression reporting.
The most informative preclinical studies combine bioluminescence + NIR-II in the same session.
NIR-II may not be necessary for superficial models or high-throughput viability screens.
Always start the modality decision with the biological endpoint, not the equipment available.

Alexis Francès

In Vivo Imaging Specialist & Global Sales Director

Alexis Francès specializes in preclinical optical imaging and leads scientific application support for Vilber’s Newton in vivo imaging systems. With more than 8 years of experience in life science, he collaborates with research teams worldwide to implement advanced imaging approaches for preclinical studies. His expertise spans optical technologies, in vivo visualization methods and application-oriented workflow development. Throughout his career, he has contributed to the deployment of cutting-edge solutions in both academic and industrial research settings. His work focuses on helping scientists achieve accurate, reproducible and publication-ready in vivo imaging results.

View other articles ➔

— READY TO SEE NEWTON IN ACTION

See our imaging solutions in your lab workflow

30-minute personalized demo with a Vilber imaging specialist. No commitment.

Book a demo

When to Use NIR-II Imaging — and When Not To

TABLE OF CONTENTS

When to Use NIR-II Imaging — and When Not To

SUMMARY

The decision in 30 seconds‍

When to use NIR-II

1 — Deep-tissue imaging where scattering limits NIR-I

Use NIR-II when:

2 — Real-time drug distribution and metabolic imaging

NIR-II is particularly well suited for:

2 — Cardiovascular mapping

The reduced scattering in NIR-II allows improved visualization of:

4 — Probe development and validation

NIR-II is increasingly used in the development of:

When bioluminescence is the better choice

1 — Detection of molecular and cellular activity

Bioluminescence offers:

When to combine modalities

When NIR-II may not be necessary

Decision framework

Choose NIR-II when the limiting factor is:

Choose bioluminescence when the limiting factor is:

Frequently asked questions

What to remember

— READY TO SEE NEWTON IN ACTION

See our imaging solutions in your lab workflow

Subscribe to our newsletter